Informace o publikaci

Proenkephalin Improves Cardio-Renal Risk Prediction in Acute Coronary Syndromes: The KID-ACS Score

Autoři	WENZL Florian A WANG Peizhi ARRIGO Mattia PAŘENICA Jiří JONES Donald J L BRUNO Francesco TARNWSKI Daniel HARTMANN Oliver BOUČEK Luboš LANG Fabian OBEID Slayman SCHOBER Andreas KRALER Simon AKHMEDOV Alexander KAHLES Florian SCHOBER Alexander OW Kok Weng MINISTRINI Stefano CAMICI Giovanni G BERGMANN Andreas LIBERALE Luca JARKOVSKY Jiri SCHWEIGER Victor SANDHU Jatinderpal K ECKARDSTEIN Arnold von TEMPLIN Christian MULLER Olivier ONDRÚŠ Tomáš JANET-JACQUELINE Olic ROFFI Marco RÄBER Lorenz CAO Thong H JUNGBAUER Carsten G NG Leong L MEBAZAA Alexandre LÜSCHER Thomas F
Rok publikování	2024
Druh	Článek v odborném periodiku
Časopis / Zdroj	European Heart Journal
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae602/7742743
Doi	http://dx.doi.org/10.1093/eurheartj/ehae602
Popis	Background and Aims Circulating proenkephalin (PENK) is a stable endogenous polypeptide with fast response to glomerular dysfunction and tubular damage. This study examined the predictive value of PENK for renal outcomes and mortality in patients with acute coronary syndromes (ACS). Methods Proenkephalin was measured in plasma in a prospective multicentre ACS cohort from Switzerland (n=4787) and in validation cohorts from the UK (n=1141), Czechia (n=927), and Germany (n=220). A biomarker-enhanced risk score (KID-ACS score) for simultaneous prediction of in-hospital acute kidney injury (AKI) and 30-day mortality was derived and externally validated. Results On multivariable adjustment for established risk factors, circulating PENK remained associated with in-hospital AKI (per log2 increase: adjusted odds ratio [OR] 1.53, 95% confidence interval [CI] 1.13–2.09, P=0.007) and 30-day mortality (adjusted hazard ratio [HR] 2.73, 95% CI 1.85–4.02, P<0.001). The KID-ACS score integrates PENK and showed an area under the receiver operating characteristic curve (AUC) of 0.72 (95% CI 0.68–0.76) for in-hospital AKI, and of 0.91 (95% CI 0.87–0.95) for 30-day mortality in the derivation cohort. Upon external validation, KID-ACS achieved similarly high performance for in-hospital AKI (Zurich: AUC 0.73, 95% CI 0.70–0.77; Czechia: AUC 0.75, 95% CI 0.68–0.81; Germany: AUC 0.71, 95% CI 0.55–0.87) and 30-day mortality (UK: AUC 0.87, 95% CI 0.83–0.91; Czechia: AUC 0.91, 95% CI 0.87–0.94; Germany: AUC 0.96, 95% CI 0.92–1.00) outperforming the CA-AKI score and the GRACE 2.0 score, respectively. Conclusions Circulating PENK offers incremental value for predicting in-hospital AKI and mortality in ACS. The simple 6-item KID-ACS risk score integrates PENK and provides a novel tool for simultaneous assessment of renal and mortality risk in patients with ACS.